Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

INTRODUCTION: The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary function (%FVC < 50%) of patients with idiopathic pulmonary fibrosis (IPF). However, there is no sufficient evidence in real world. OBJECTIVES: Reveal the utility and...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Mitsuhiro, Tsushima, Kenji, Sakayori, Masashi, Suzuki, Kenichi, Ikari, Jun, Terada, Jiro, Tatsumi, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186773/
https://www.ncbi.nlm.nih.gov/pubmed/30349191
http://dx.doi.org/10.2147/DDDT.S179427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186773/
https://www.ncbi.nlm.nih.gov/pubmed/30349191
http://dx.doi.org/10.2147/DDDT.S179427

Ejemplares similares